The New York Times @nytimes
Breaking News: A congressional report faulted the FDA approval process for the Alzheimer’s drug Aduhelm and criticized Biogen for its $56,000-a-year price. https://t.co/BwpFN5f1xE — PolitiTweet.org
Created
Thu Dec 29 18:05:48 +0000 2022
Likes
201
Retweets
85
Source
SocialFlow
View Raw Data
JSON DataView on Twitter
Likely Available
The New York Times @nytimes
Breaking News: A congressional report faulted the FDA approval process for the Alzheimer’s drug Aduhelm and criticized Biogen for its $56,000-a-year price. https://t.co/BwpFN5f1xE — PolitiTweet.org